Network meta-analysis of 15 RCTs (3,642 patients) with severe chronic rhinosinusitis with nasal polyps: dupilumab and stapokibart (20–24 weeks) and dupilumab and tezepelumab (48–56 weeks) reduced polyp and congestion scores more than other biologics; safety was comparable.
Meta-analysisn = 3,642
Ouranos et al. Comparative efficacy of biologic agents for severe chronic rhinosinusitis with nasal polyps: Systematic review and network meta-analysis